Molecular mechanisms of bortezomib resistant adenocarcinoma cells

• Published in: PloS one Vol. 6; no. 12; p. e27996
• Main Authors: Suzuki, Erika, Demo, Susan, Deu, Edgar, Keats, Jonathan, Arastu-Kapur, Shirin, Bergsagel, P Leif, Bennett, Mark K, Kirk, Christopher J
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 22.12.2011; Public Library of Science (PLoS)
• Subjects: Adenocarcinoma; Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Antineoplastic Agents - therapeutic use; Binding sites; Biology; Blotting, Western; Boronic Acids - therapeutic use; Bortezomib; Cancer; Cell culture; Cell Line, Tumor; Cycloheximide; Cytotoxicity; Drug Resistance, Neoplasm; Enzyme inhibitors; Enzyme-Linked Immunosorbent Assay; Exposure; FDA approval; Gene expression; Genomics; Humans; Inhibition; Inhibitors; Lymphoma; Medicine; Molecular modelling; Multiple myeloma; Mutation; Patients; Penicillin; Pharmaceuticals; Proteasomes; Proteins; Pyrazines - therapeutic use; Recovery; Stress response; Thermal resistance; South San Francisco California; California; United States > US; Arizona
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0027996

Bortezomib (Velcade™) is a reversible proteasome inhibitor that is approved for the treatment of multiple myeloma (MM). Despite its demonstrated clinical success, some patients are deprived of treatment due to primary refractoriness or development of resistance during therapy. To investigate the role of the duration of proteasome inhibition in the anti-tumor response of bortezomib, we established clonal isolates of HT-29 adenocarcinoma cells adapted to continuous exposure of bortezomib. These cells were ~30-fold resistant to bortezomib. Two novel and distinct mutations in the β5 subunit, Cys63Phe, located distal to the binding site in a helix critical for drug binding, and Arg24Cys, found in the propeptide region were found in all resistant clones. The latter mutation is a natural variant found to be elevated in frequency in patients with MM. Proteasome activity and levels of both the constitutive and immunoproteasome were increased in resistant cells, which correlated to an increase in subunit gene expression. These changes correlated with a more rapid recovery of proteasome activity following brief exposure to bortezomib. Increased recovery rate was not due to increased proteasome turnover as similar findings were seen in cells co-treated with cycloheximide. When we exposed resistant cells to the irreversible proteasome inhibitor carfilzomib we noted a slower rate of recovery of proteasome activity as compared to bortezomib in both parental and resistant cells. Importantly, carfilzomib maintained its cytotoxic potential in the bortezomib resistant cell lines. Therefore, resistance to bortezomib, can be overcome with irreversible inhibitors, suggesting prolonged proteasome inhibition induces a more potent anti-tumor response.